1. Home
  2. IMAX vs NBTX Comparison

IMAX vs NBTX Comparison

Compare IMAX & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Imax Corporation

IMAX

Imax Corporation

N/A

Current Price

$52.60

Market Cap

2.4B

Sector

N/A

ML Signal

N/A

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

N/A

Current Price

$34.03

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IMAX
NBTX
Founded
1967
2003
Country
Canada
France
Employees
N/A
97
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.0B
IPO Year
1997
2018

Fundamental Metrics

Financial Performance
Metric
IMAX
NBTX
Price
$52.60
$34.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
1
Target Price
$44.50
$36.00
AVG Volume (30 Days)
920.6K
132.0K
Earning Date
04-30-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
31.25
N/A
EPS
0.35
N/A
Revenue
$410,212,000.00
N/A
Revenue This Year
$9.79
$58.17
Revenue Next Year
$7.51
N/A
P/E Ratio
$150.77
N/A
Revenue Growth
16.47
N/A
52 Week Low
$30.74
$9.72
52 Week High
$55.57
$57.14

Technical Indicators

Market Signals
Indicator
IMAX
NBTX
Relative Strength Index (RSI) 57.15 39.57
Support Level $50.03 $34.97
Resistance Level $55.57 $41.99
Average True Range (ATR) 1.51 2.54
MACD -0.23 -0.73
Stochastic Oscillator 57.93 3.18

Price Performance

Historical Comparison
IMAX
NBTX

About IMAX Imax Corporation

Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Share on Social Networks: